Esperion Therapeutics (ESPR) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Esperion Therapeutics Revenue Highlights

Latest Revenue (Y)

$116.33M

Latest Revenue (Q)

$51.63M

Main Segment (Y)

Product

Esperion Therapeutics Revenue by Period

Esperion Therapeutics Revenue by Year

Date	Revenue	Change
2023-12-31	$116.33M	54.14%
2022-12-31	$75.47M	-3.79%
2021-12-31	$78.45M	-65.52%
2020-12-31	$227.55M	53.37%
2019-12-31	$148.36M	-19.57%
2018-12-31	$184.47M	100.00%
2017-12-31	-	100.00%
2016-12-31	-	100.00%
2015-12-31	-	100.00%
2014-12-31	-	-100.00%
2013-12-31	$4.98B	100.00%
2012-12-31	-	100.00%
2011-12-31	-	100.00%
2002-12-31	-	100.00%
2001-12-31	-	-100.00%
2000-12-31	$2.00K	100.00%
1999-12-31	-	-

Esperion Therapeutics generated $116.33M in revenue during NA 2023, up 54.14% compared to the previous quarter, and up 63.06% compared to the same period a year ago.

Esperion Therapeutics Revenue by Quarter

Date	Revenue	Change
2024-09-30	$51.63M	-30.07%
2024-06-30	$73.83M	-46.39%
2024-03-31	$137.74M	327.09%
2023-12-31	$32.25M	-5.06%
2023-09-30	$33.97M	31.73%
2023-06-30	$25.79M	5.99%
2023-03-31	$24.33M	29.29%
2022-12-31	$18.82M	-0.85%
2022-09-30	$18.98M	0.74%
2022-06-30	$18.84M	0.03%
2022-03-31	$18.84M	22.30%
2021-12-31	$15.40M	6.88%
2021-09-30	$14.41M	-64.56%
2021-06-30	$40.66M	409.64%
2021-03-31	$7.98M	-17.22%
2020-12-31	$9.64M	151.45%
2020-09-30	$3.83M	-98.19%
2020-06-30	$212.24M	11434.57%
2020-03-31	$1.84M	87.37%
2019-12-31	$982.00K	0.10%
2019-09-30	$981.00K	-0.10%
2019-06-30	$982.00K	-99.32%
2019-03-31	$145.42M	-21.17%
2018-12-31	$184.47M	100.00%
2018-09-30	-	100.00%
2018-06-30	-	100.00%
2018-03-31	-	100.00%
2017-12-31	-	100.00%
2017-09-30	-	100.00%
2017-06-30	-	100.00%
2017-03-31	-	100.00%
2016-12-31	-	100.00%
2016-09-30	-	100.00%
2016-06-30	-	100.00%
2016-03-31	-	100.00%
2015-12-31	-	100.00%
2015-09-30	-	100.00%
2015-06-30	-	100.00%
2015-03-31	-	100.00%
2014-12-31	-	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	100.00%
2013-12-31	-	100.00%
2013-09-30	-	100.00%
2013-06-30	-	100.00%
2013-03-31	-	100.00%
2012-12-31	-	100.00%
2012-09-30	-	100.00%
2012-06-30	-	100.00%
2012-03-31	-	100.00%
2003-09-30	-	100.00%
2003-06-30	-	100.00%
2003-03-31	-	100.00%
2002-12-31	-	100.00%
2002-09-30	-	100.00%
2002-06-30	-	100.00%
2002-03-31	-	100.00%
2001-12-31	-	100.00%
2001-09-30	-	-100.00%
2001-06-30	$1.00K	-
2001-03-31	$1.00K	-
2000-12-31	$1.00K	-
2000-09-30	$1.00K	-
2000-06-30	$1.00K	100.00%
2000-03-31	-	-

Esperion Therapeutics generated $51.63M in revenue during Q3 2024, up -30.07% compared to the previous quarter, and up 200.23% compared to the same period a year ago.

Esperion Therapeutics Revenue Breakdown

Esperion Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Product	$78.33M	$55.86M	-	-	-
Collaboration Revenue	$38.00M	$19.61M	$38.40M	$214.58M	-
Royalty Revenue From DSE	-	-	$9.90M	-	-
Ongoing Regulatory And Development Activities Revenue	-	-	-	$1.60M	$4.00M
Product Sales Bulk Tablets And Royalty Revenue Of Nilemdo And Nustendi	-	-	-	$2.80M	-
Milestone Marketing Authorization Approval Nustendi	-	-	-	$150.00M	-
License For Intellectual Property Revenue	-	-	-	-	$144.40M

Esperion Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (67.34%), and Collaboration Revenue (32.66%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Product	$31.11M	$24.76M	$20.76M	$20.25M	$20.29M	$17.03M	$14.97M	$12.19M	$8.17M	-	-	-	-	-	-	-	-	-	-	-
Collaboration Revenue	$20.53M	$112.98M	$11.49M	$13.72M	$5.49M	$7.30M	$3.85M	$5.02M	$5.26M	$5.48M	$3.21M	$3.51M	$30.05M	$1.63M	$1.47M	$502.00K	$211.63M	$982.00K	-	-
Royalty Revenue And Product Sales Bulk Tablets	-	-	-	-	-	-	-	$4.40M	$5.00M	$5.30M	$3.30M	-	-	-	-	-	-	-	-	-
Royalty Revenue And Product Sales Bulk Tablets Nilemdo And Nustendi	-	-	-	-	-	-	-	-	-	-	-	-	$2.00M	-	-	-	-	-	-	-
Product Sales Bulk Tablets Nilemdo And Nustendi	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.60M	$500.00K	$1.00M	-	-	-	-
Milestone Marketing Authorization Approval Nustendi	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$150.00M	-	-	-
Regulatory Performance Obligations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$700.00K	-	-	-
Ongoing Regulatory Activities Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.00M	-	-
Ongoing Regulatory And Development Activities Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.00M	$1.00M
License For Intellectual Property Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Esperion Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (60.25%), and Collaboration Revenue (39.75%).

Esperion Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
ELAN	Elanco Animal Health	$4.42B	$1.18B
NBIX	Neurocrine Biosciences	$1.89B	$622.10M
ALKS	Alkermes	$1.66B	$378.14M
PBH	Prestige Consumer Healthcare	$1.13B	$283.55M
PAHC	Phibro Animal Health	$977.89M	$273.16M
PCRX	Pacira BioSciences	$674.98M	$168.57M
COLL	Collegium Pharmaceutical	$566.77M	$159.30M
ANIP	ANI Pharmaceuticals	$486.82M	$148.33M
ITCI	Intra-Cellular Therapies	$462.18M	$175.38M
IRWD	Ironwood Pharmaceuticals	$442.74M	$91.59M
KMDA	Kamada	$144.76M	$37.40M
SIGA	SIGA	$139.92M	$10.01M
LFCR	Lifecore Biomedical	$128.26M	$32.56M
ESPR	Esperion Therapeutics	$116.33M	$51.63M
RMTI	Rockwell Medical	$83.61M	$25.83M
AVDL	Avadel Pharmaceuticals	$27.96M	$50.02M

ESPR Revenue FAQ

What is Esperion Therapeutics’s yearly revenue?

Esperion Therapeutics's yearly revenue for 2023 was $116.33M, representing an increase of 54.14% compared to 2022. The company's yearly revenue for 2022 was $75.48M, representing a decrease of -3.79% compared to 2021. ESPR's yearly revenue for 2021 was $78.45M, representing a decrease of -65.52% compared to 2020.

What is Esperion Therapeutics’s quarterly revenue?

Esperion Therapeutics's quarterly revenue for Q3 2024 was $51.63M, a -30.07% decrease from the previous quarter (Q2 2024), and a 52.00% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $73.83M, a -46.39% decrease from the previous quarter (Q1 2024), and a 186.33% increase year-over-year (Q2 2023). ESPR's quarterly revenue for Q1 2024 was $137.74M, a 327.09% increase from the previous quarter (Q4 2023), and a 466.14% increase year-over-year (Q1 2023).

What is Esperion Therapeutics’s revenue growth rate?

Esperion Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 48.30%, and for the last 5 years (2019-2023) was -21.59%.

What are Esperion Therapeutics’s revenue streams?

Esperion Therapeutics's revenue streams in c 23 are Product, and Collaboration Revenue. Product generated $78.34M in revenue, accounting 67.34% of the company's total revenue, up 40.23% year-over-year. Collaboration Revenue generated $38M in revenue, accounting 32.66% of the company's total revenue, up 93.75% year-over-year.

What is Esperion Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Esperion Therapeutics was Product. This segment made a revenue of $78.34M, representing 67.34% of the company's total revenue.